Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200883 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL764093 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL55610 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL116439 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL55611 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL873280 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL193111 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL312687 | 1.00 | ATM (0.59) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL4275881 | 0.98 | ATM (0.57) | ATMCYP1A2POLBCYP3A4CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL29062671 | 0.98 | ATM (0.57) | ATMCYP1A2POLBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 621 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060926-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SAIL BIOMEDICINES INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12534470-B2 | DNA polymerase IIIC inhibitors and use thereof | Acurx Pharmaceuticals, Inc. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | NURIX THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4678238-A2 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| US-12522593-B2 | Azacycloalkyl carbonyl cyclic amine compound | ALIVEXIS, INC. (JP) | 2026-01-13 | — | — | US | disclosed |
| US-20260001875-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE | UNIV DUNDEE (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250360141-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-11-27 | — | — | US | disclosed |
| US-20250313578-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2025-10-09 | — | — | US | disclosed |
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2025-10-07 | — | — | US | disclosed |
| US-5385889-A | Substitution of L-proline at the 7-position of the peptide hormone with a D-configuration hydroxyproline ether or thioether converts agonist into antagonist | SCIOS NOVA INC. (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0618810-A4 | BRADYKININ ANTAGONIST PEPTIDES. | SCIOS NOVA INC (US) | 1994-12-07 | — | — | EP | disclosed |
| EP-0618809-A1 | BRADYKININ TYPE PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| EP-0618810-A1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| EP-0618809-A4 | BRADYKININ TYPE PEPTIDES. | SCIOS NOVA INC (US) | 1994-07-28 | — | — | EP | disclosed |
| EP-0560269-A1 | Substituted pyrrolidine derivatives as HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | disclosed |
| WO-1992018156-A1 | BRADYKININ ANTAGONIST PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992018155-A1 | BRADYKININ TYPE PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | disclosed |
| US-4902684-A | Benzazepine and benzothiazepine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1990-02-20 | — | — | US | disclosed |
| WO-1989012633-A1 | BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | E.R. SQUIBB & SONS, INC. (US) | 1989-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | ATM 3391/4885CYP1A2 202/4885POLB 1659/4885 |
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | IRAK1, IRAK2, IRAK3 | ATM 800/4885CYP1A2 4523/4885POLB 1592/4885 |
| US-20250313578-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ATM 4098/4885CYP1A2 234/4885POLB 1812/4885 |
| US-20260060926-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SGMS1, NPC1L1, SGMS2 | ATM 3641/4885CYP1A2 4683/4885POLB 3115/4885 |
| US-12534470-B2 | DNA polymerase IIIC inhibitors and use thereof | POLR1A, POLR2H, POLN | ATM 3788/4885CYP1A2 1600/4885POLB 4/4885 |
| US-20260001875-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE | LRRK2, XIAP, PARK7 | ATM 622/4885CYP1A2 4251/4885POLB 2700/4885 |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | DDX21, PHAX, RBX1 | ATM 4453/4885CYP1A2 4720/4885POLB 2834/4885 |
| US-20250360141-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | CGAS, GLS2, GMPS | ATM 351/4885CYP1A2 647/4885POLB 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.